Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.39 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893148 | 1.00 | CYP3A4 (0.43) | CYP3A4MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL893844 | 0.83 | CYP3A4 (0.47) | CYP3A4MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL893846 | 0.82 | CYP3A4 (0.59) | CYP3A4 | |
| SCHEMBL14118795 | 0.82 | CYP3A4 (0.59) | CYP3A4 | |
| SCHEMBL14118793 | 0.82 | CYP3A4 (0.59) | CYP3A4 | |
| SCHEMBL893754 | 0.80 | UGT1A1 (0.46) | CYP3A4MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL4396378 | 0.76 | NR1I2 (0.36) | CYP3A4MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL4961909 | 0.76 | UGT1A1 (0.55) | CYP3A4MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL4961920 | 0.76 | UGT1A1 (0.55) | CYP3A4MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL4395637 | 0.76 | UGT1A1 (0.42) | CYP3A4MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CYP3A4 8/4885MLNR 1233/4885NR1I2 327/4885 |
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CYP3A4 8/4885MLNR 1233/4885NR1I2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.